HIV+Hep’s Carl Schmid, a consumer representative to the National Association of Insurance Commissioners (NAIC), presents to the NAIC PBM subgroup, along with ACSCAN’s Anna Howard, on how PBM’s impact patient access and affordability of prescription drugs.
Details the harmful impacts copay accumulators have on drug adherence and patients costs, federal and state actions taken to date to ensure copay assistance counts, and advocacy opportunities at the federal and state levels patient groups can engage in relative to copay accumulators.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Details policies and programs needed to ensure and promote PrEP access to #endHIV: reviewing insurance plans to see if they follow the ACA requirement to cover PrEP w/o patient cost-sharing, the need for greater funding of @CDC_HIVAIDS & community health centers, & potential USPSTF evaluation of long-acting PrEP products
Provides details on how insurers’ treatment of manufacturer copay assistance affects patients’ out-of-pocket spending and how high costs drive up prescription abandonment rates, especially while patients deal with the economic effects of COVID.